Experimental cell therapy targets Hard-to-Treat myeloma
NCT ID NCT04960579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses donor immune cells that are engineered to find and attack myeloma cells. The main goals are to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
P-BCMA-ALLO1 (a type of immune cell therapy that targets cancer cells)
What this could lead to
If successful, this could provide a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong
This is an early-phase trial, so the therapy may not work or could cause serious side effects like cytokine release syndrome. It is not yet proven to be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advocate Aurora Health
Park Ridge, Illinois, 66068, United States
-
Blood Marrow and Transplant Group of Georgia
Atlanta, Georgia, 30342, United States
-
City of Hope
Goodyear, Arizona, 85338, United States
-
City of Hope
Chicago, Illinois, 60099, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute - Methodist Healthcare
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute - St. David's South Austin Medical Center
Austin, Texas, 78704, United States
-
University of California San Diego
San Diego, California, 92093, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-1350, United States
-
University of Oklahoma, Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4238, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Wayne State - Karmanos Cancer Institute
Detroit, Michigan, 48201, United States